Leerink Partnrs Has Pessimistic View of ALDX FY2028 Earnings

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) – Investment analysts at Leerink Partnrs dropped their FY2028 earnings per share (EPS) estimates for shares of Aldeyra Therapeutics in a report issued on Wednesday, November 13th. Leerink Partnrs analyst M. Goodman now expects that the biotechnology company will earn $2.50 per share for the year, down from their previous forecast of $2.55. The consensus estimate for Aldeyra Therapeutics’ current full-year earnings is ($0.48) per share.

Separately, HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Aldeyra Therapeutics in a research note on Friday, August 9th.

Aldeyra Therapeutics Trading Down 1.4 %

ALDX opened at $4.21 on Friday. The company’s 50 day moving average is $5.45 and its 200 day moving average is $4.60. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.80 and a quick ratio of 6.80. Aldeyra Therapeutics has a 12-month low of $2.43 and a 12-month high of $6.55.

Aldeyra Therapeutics (NASDAQ:ALDX) last posted its earnings results on Thursday, November 7th. The biotechnology company reported ($0.25) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.25).

Institutional Investors Weigh In On Aldeyra Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Perceptive Advisors LLC raised its holdings in Aldeyra Therapeutics by 7.9% during the second quarter. Perceptive Advisors LLC now owns 9,275,851 shares of the biotechnology company’s stock valued at $30,703,000 after acquiring an additional 682,265 shares during the period. Federated Hermes Inc. purchased a new position in Aldeyra Therapeutics in the 2nd quarter worth approximately $1,758,000. PFG Investments LLC bought a new position in Aldeyra Therapeutics in the 2nd quarter worth approximately $1,312,000. Jacobs Levy Equity Management Inc. raised its position in shares of Aldeyra Therapeutics by 163.4% during the third quarter. Jacobs Levy Equity Management Inc. now owns 476,949 shares of the biotechnology company’s stock valued at $2,571,000 after buying an additional 295,864 shares during the last quarter. Finally, Acadian Asset Management LLC lifted its holdings in shares of Aldeyra Therapeutics by 106.3% in the first quarter. Acadian Asset Management LLC now owns 452,449 shares of the biotechnology company’s stock worth $1,478,000 after buying an additional 233,169 shares in the last quarter. Institutional investors own 59.71% of the company’s stock.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.